A Phase II Evaluation Of OSI-774 (NSC #718781) In The Treatment Of Persistent or Recurrent Squamous Cell Carcinoma Of The Cervix.
Latest Information Update: 17 Sep 2021
At a glance
- Drugs Erlotinib (Primary)
- Indications Cervical cancer
- Focus Adverse reactions; Biomarker; Therapeutic Use
- 22 Aug 2005 New trial record.